Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04719650
Other study ID # M2020427
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date October 2021
Est. completion date November 2024

Study information

Verified date January 2021
Source Peking University Third Hospital
Contact Qi Liu, Ph. D.
Phone +8615501060136
Email liuqicpu@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The recommended dosing regimen of zoledronic acid in Chinese osteoporosis patients is completely in accordance with the one of 5 mg per year abroad that based on the dosing regimen in Paget's disease. This dosing regimen lacks the actual supportive clinical data of Chinese patients. In addition, the overall incidence of acute phase response, the main adverse event after the first infusion, in Chinese patients is higher than that in Caucasian patients population. Moreover, the results of the similar drug clinical study in the Japanese patients shown that the purpose of effective treatment for osteoporosis could be achieved with half of the dosage in Caucasian population. Thus, it could be inferred from these that the dosing regimen of zoledronic acid might be inappropriate in Chinese osteoporosis patients. Therefore, the main purpose of this clinical trail is to compare the zoledronic acid pharmacokinetic and pharmacodynamic characteristic of different doses in Chinese postmenopausal subjects with low bone mass or osteoporosis and explore the best dosing regimen in Chinese patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 64
Est. completion date November 2024
Est. primary completion date October 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 60 Years to 70 Years
Eligibility Inclusion Criteria: 1. Chinese postmenopausal women 2. Aged between 60 and 70. 3. Bone mineral density (BMD) values of less than 1 standard deviations (SD) below the normal adult mean. 4. Willing to participate in this study. Exclusion Criteria: 1. Hypersensitivity to zoledronic acid or other bisphosphonate or zoledronic acid formulation (excipients). 2. Secondary osteoporosis. 3. Receiving the following drugs that affect bone metabolism prior to randomization: (1) intravenous biphosphonates or denosumab. (2) oral biphosphonates, parathyroid hormone or its analogues, strontium, or fluoride within 12 months. (3) glucocorticoid, steroids, immunosuppressive agents, calcitonin, calcitriol or its analogues, thiazides diuretics, long-acting estrogen/progesterone, or statins within 3 months. 4. Combine other diseases affect bone metabolism: osteogenesis imperfecta, hyperthyroidism, malignant tumors, Paget's disease, rheumatoid arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, liver failure, or renal failure. 5. Hyperthyroidism or hypothyroidism during screening. 6. Treatment with any investigational drug within the past 3 months. 7. Creatinine clearance < 35 mL/min. 8. 25(OH)D level< 20 ng/mL. 9. Serum calcium level < 2.0 mmol/L (8 mg/dL), or >2.8 mmol/L (11.0 mg/dL). 10. Fever, severe infections, severe injuries, or major surgical operation within 30 days. 11. ECG corrected QT interval (QTc) > 480 ms. 12. Pending invasive dental procedure or in progress. 13. History of smoking within 6 months. 14. Diabetes with fasting blood glucose = 7.0 mmol/L, or glycated hemoglobin (HbA1c) >6.3%. 15. History of drug or alcohol abuse. 16. History of stroke, cerebral ischemic stroke, or cerebral hemorrhage. 17. Any physiological or medical condition which, in the opinion of the investigator, would preclude the participant from this trail.

Study Design


Intervention

Drug:
Zoledronic Acid Injection
Infusion 1mg zoledronic acid once.
Zoledronic Acid Injection
Infusion 2.5mg zoledronic acid once.
Zoledronic Acid Injection
Infusion 5mg zoledronic acid once.
Placebo
Infusion normal saline once.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

References & Publications (3)

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. Erratum in: Osteoporos Int. 2015 Jul;26(7):2045-7. — View Citation

Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis. Orthop Surg. 2017 Aug;9(3):284-289. doi: 10.1111/os.12338. — View Citation

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int. 2003 May;14(3):225-34. Epub 2003 Apr 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of Zoledronic acid Zoledronic acid concentration in plasma and urine. Predose, 30 minutes, 2 hours, 24 hours, day 7, day 29, 3 months, 6 months, 12 months, 24 months, and 36 months post dose
Primary Maximum concentration of Zoledronic acid The observed maximum concentration following administration (Cmax) in plasma after zoledronic acid infusion. 0-36 months
Primary Time to reach maximum concentration of Zoledronic acid The time to reach the maximum concentration after administration (Tmax) in plasma after zoledronic acid infusion. 0-36 months
Primary AUC of Zoledronic acid The area under the concentration-time curve (AUC) in plasma after zoledronic acid infusion. 0-36 months
Primary terminal half-life of Zoledronic acid The terminal half-life (t1/2) of zoledronic acid after administration. 0-36 months
Primary apparent clearance of Zoledronic acid The apparent clearance (CL/F) of zoledronic acid after administration. 0-36 months
Primary apparent volume of distribution of Zoledronic acid The apparent volume of distribution of zoledronic acid after administration. 0-36 months
Primary Concentration of bone turnover markers Concentration-time profile of procollagen type 1 N-propeptide (P1NP), bone-specific alkaline phosphatase (ALP), osteocalcin (OCN), C-telopeptide (CTx), and tartrate-resistant acid phosphatase 5b (TRACP-5b) with unit of ng/mL. 0-36 months
Primary Concentration of 25(OH)D and FGF23 Concentration determination of 25(OH)D and fibroblast growth factor 23 (FGF23) with unit of ng/mL 0-36 months
Primary PTH concentration determination Assessment of the profile of parathyroid hormone (PTH) 0-36 months
Primary Serum sclerostin concentration determination Concentration-time profile of sclerostin (SOST) after zoledronic acid infusion. 0-36 months
Primary Pharmacodynamic of zoledronic acid Assessment of lipid metabolism markers, such as low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol, and triglycerides. 0-36 months
Primary Pharmacodynamic of zoledronic acid Assessment of fibroblast growth factor 19 (FGF19). 0-36 months
Primary Pharmacodynamic of zoledronic acid Assessment of total bile acid. 0-36 months
Primary Pharmacodynamic of zoledronic acid Assessment of bone mineral density at the lumbar spine, neck of femur, and total hip. 0-36 months
Primary Change of immune indicator Changes in white blood cells(WBC) 0-36 months
Primary Change of immune indicator Changes in C reaction protein (CRP) 0-36 months
Primary Change of immune indicator Changes in interferon-? (IFN-?) 0-36 months
Primary Change of immune indicator Changes in interleukin-6 (IL-6) 0-36 months
Primary Change of immune indicator Changes in ?dT cells activation 0-36 months
Secondary Incidence of adverse event The occurrence time and severity of fracture. The occurrence time and severity of acute phase response. The occurrence time and severity of other adverse event. 0-36 months
See also
  Status Clinical Trial Phase
Recruiting NCT05902078 - Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis Phase 4
Completed NCT05087030 - Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis Phase 3
Completed NCT01544894 - Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Phase 4
Completed NCT00377819 - Study of Transitioning From Alendronate to Denosumab Phase 3
Completed NCT00381251 - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation. Phase 1
Completed NCT00239629 - Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial Phase 4
Completed NCT04026256 - Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Phase 4
Terminated NCT00529373 - A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) Phase 3
Completed NCT00092014 - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) Phase 3
Recruiting NCT06079476 - A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture. Phase 4
Recruiting NCT02981732 - CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome N/A
Completed NCT01709110 - VERtebral Fracture Treatment Comparisons in Osteoporotic Women Phase 4
Completed NCT01348243 - Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis Phase 3
Completed NCT00541658 - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis Phase 3
Completed NCT00395395 - Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women Phase 1
Completed NCT00247273 - A Study of Monthly Risedronate for Osteoporosis Phase 3
Active, not recruiting NCT03720886 - G56W1 in Women With Postmenopausal Osteoporosis Phase 1/Phase 2
Completed NCT01668589 - Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis N/A
Completed NCT04664959 - A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis Phase 3
Not yet recruiting NCT04719481 - Pravastatin Reduces Acute Phase Response of Zoledronic Acid Phase 4